Compass Therapeutics (CMPX) Other Operating Expenses (2021 - 2022)

Compass Therapeutics (CMPX) reported Other Operating Expenses of $69000.0 for Q2 2022, up 56.82% sequentially from $44000.0 in Q1 2021.

Compass Therapeutics (CMPX) Other Operating Expenses (2021 - 2022) Analysis & Trends

Compass Therapeutics (CMPX) has 2 years of Other Operating Expenses data on file, last reported at $69000.0 in Q2 2022.

For the quarter ending Q2 2022, Other Operating Expenses changed N/A year-over-year to $69000.0; the trailing twelve-month figure through Mar 2023 stood at $69000.0 (changed N/A YoY), and the FY2021 full-year result was $50.6 million, up 18113.52% from the prior year.
Other Operating Expenses rose to $69000.0 in Q2 2022, from $44000.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $69000.0 in Q2 2022 to a low of $44000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Compass Therapeutics	388.64 Mn	193.96 Mn	-

Download Data

Date	Value
Jun 30, 2022	69,000.00
Mar 31, 2021	44,000.00